Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļPCSA
āļāļ·āđāļāļāļĢāļīāļĐāļąāļProcessa Pharmaceuticals Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 07, 2013
āļāļĩāļāļĩāđāļNg (George K)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ10
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļOct 07
āļāļĩāđāļāļĒāļđāđ601 21St Street, Suite 300
āđāļĄāļ·āļāļVERO BEACH
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ32960
āđāļāļĢāļĻāļąāļāļāđ14437763133
āđāļ§āđāļāđāļāļāđhttps://www.processapharmaceuticals.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļPCSA
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 07, 2013
āļāļĩāļāļĩāđāļNg (George K)
Mr. George K. Ng
Chief Executive Officer, Director
Chief Executive Officer, Director
Dr. David Young, Ph.D.
President - Research and Development, Director
President - Research and Development, Director
Mr. Russell L. Skibsted
Chief Financial Officer
Mr. Patrick Lin
Chief Business and Strategy Officer
Chief Business and Strategy Officer
Ms. Wendy Guy
Founder, Chief Administrative Officer
Founder, Chief Administrative Officer
Dr. Sian Bigora, Pharm.D.
Dr. Sian Bigora, Pharm.D.
Chief Development Officer and Regulatory Officer, Founder
Chief Development Officer and Regulatory Officer, Founder
Mr. Khoso Baluch
Independent Director
Mr. Justin W. Yorke
Independent Chairman of the Board
Independent Chairman of the Board
Ms. Geraldine Liu Pannu
Independent Director
Mr. James R. (Jim) Neal
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. George K. Ng
Chief Executive Officer, Director
Chief Executive Officer, Director
Dr. David Young, Ph.D.
President - Research and Development, Director
President - Research and Development, Director
Mr. Russell L. Skibsted
Chief Financial Officer
Mr. Patrick Lin
Chief Business and Strategy Officer
Chief Business and Strategy Officer
Ms. Wendy Guy
Founder, Chief Administrative Officer
Founder, Chief Administrative Officer
Dr. Sian Bigora, Pharm.D.
Dr. Sian Bigora, Pharm.D.
Chief Development Officer and Regulatory Officer, Founder
Chief Development Officer and Regulatory Officer, Founder